GHTC delivers statement on antimicrobial resistance at WHO Executive Board meeting
The following statement from Global Health Council, supported by the Global Health Technologies Coalition and the Infectious Diseases Society of America was delivered at the 148th session of the WHO Executive Board on Agenda Item 9: Antimicrobial resistance.
The Global Health Council, Global Health Technologies Coalition, and Infectious Diseases Society of America thank the chair and distinguished delegates for this opportunity to comment on the ongoing work against resistance to antimicrobials from a large span of bacterial, viral, parasitic, and fungal microorganisms.
According to a recent
Lancet study, bacterial infections unsuccessfully treated due to antimicrobial resistance (AMR) claim at least 700,000 lives per year worldwide and are projected to be associated with the deaths of 10 million people per year by 2050.
GHC Statement on Antimicrobial Resistance at the 148th Session of WHO Executive Board Meeting
January 25, 2021
The following statement from Global Health Council, supported by the Global Health Technologies Coalition and the Infectious Diseases Society of America was submitted to the 148th session of the WHO Executive Board on Agenda Item 9: Antimicrobial resistance.
The Global Health Council, Global Health Technologies Coalition, and Infectious Diseases Society of America thank the chair and distinguished delegates for this opportunity to comment on the ongoing work against resistance to antimicrobials from a large span of bacterial, viral, parasitic, and fungal microorganisms.
According to a recent